Table 1. Summary results of meta-analysis and indirect treatment comparison.

Variable a	Comparison Type	Group	Results [Mean difference (95%CI)]	P values
HbA1c, %
	Meta-analysis	Dapagliflozin vs. Placebo	–0.82 [–0.95, –0.68]	< 0.00001
	Meta-analysis	Acarbose vs. Placebo	–0.47 [–0.86, –0.07]	0.02
	ITC	Dapagliflozin vs. Acarbose	–0.35 [–0.767, 0.067]	0.45572
SBP, mmHg
	Meta-analysis	Dapagliflozin vs. Placebo	–4.30 [–6.94, –1.67]	0.001
	Meta-analysis	Acarbose vs. Placebo	–0.17 [–4.51, 4.17]	0.94
	ITC	Dapagliflozin vs. Acarbose	–4.13 [–9.207, 0.947]	--
Body Weight, kg
	Meta-analysis	Dapagliflozin vs. Placebo	–1.91 [–2.31, –1.50]	< 0.00001
	Meta-analysis	Acarbose vs. Placebo	–1.41 [–2.63, –0.18]	0.02
	ITC	Dapagliflozin vs. Acarbose	–0.50 [–1.79, 0.79]	0.79383

HbA1c, glycated hemoglobin; ITC, indirect treatment comparison; SBP, systolic blood pressure.

^a Variables were taken from data of 4 included placebo-controlled studies [41–42,55–56].